Predictor of Major Adverse Cardiac Event (MACE) in Acute Coronary Syndrome (ACS) patients: A Scoping Review
DOI:
https://doi.org/10.35654/ijnhs.v5i4.634Keywords:
Adult, MACE, ACSAbstract
Introduction: Acute Coronary Syndrome (ACS) is a contributor to morbidity and mortality rates every year. The cause of death in ACS is a complication known as a MACE. However, it has not been known what can trigger the occurrence of MACE after post-ACS treatment. Objective: This study aimed to review and assess conditions that could predict the occurrence of MACE after treatment of ACS patients. Method: We conducted literature on articles between 2016-2021 with four databases: PubMed, Science Direct, CINAHL, and the search engine, namely Google Scholar. The design used is a scoping review. Five independent reviewers analyzed the inclusion and exclusion criteria. The researchers drew data from each article: author, year, region, purpose, design, related factors, and results. Furthermore, the researchers used PRISMA to compile the manuscript. There were 30 articles included in the analysis. One thousand articles were obtained through a basic data search based on the PRISMA flowchart, and after finding the manual, 30 studies were identified. Researchers selected relevant articles, namely predictors associated with MACE after treatment of ACS patients. Result: The results found that the predictors associated with MACE in ACS were comorbidities, adherence to hemodynamics medication, clinical parameters, the severity of atherosclerosis, increased cardiac disease assessment scores, and psychosocial disorder.
Downloads
References
World Health Organization (WHO). Cardiovascular Diseases (CVDs) Geneva, Switzerland: WHO; 2020 [Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
Black JM, Hawks JH. Keperawatan Medikal Bedah : Manajemen Klinis untuk Hasil yang Diharapkan. 8 E, editor. Singapure: Elsevier; 2014.
Pangestika DD, Trisyani Y, Nur'aeni A. The Effect of Dhikr Therapy on the Cardiac Chest Pain of Acute Coronary Syndrome (ACS) Patients. Nurse Media Jurnal of Nursing. 2020;Volume 10 Nomor 2.
KEMENKES. Riset Kesehatan Dasar Tahun 2016 Jakarta: KEMENKES RI; 2016 [Available from: https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf.
Attar R, Valentin JB, Freeman P, Andell P, Aagaard J, Jensen SE. The effect of schizophrenia on major adverse cardiac events, length of hospital stay, and prevalence of somatic comorbidities following acute coronary syndrome. European heart journal Quality of care & clinical outcomes. 2019;5(2):121-6.
Attar R, Wester A, Koul S, Eggert S, Polcwiartek C, Jernberg T, et al. Higher risk of major adverse cardiac events after acute myocardial infarction in patients with schizophrenia. Open heart. 2020;7(2).
Barger LK, Rajaratnam SMW, Cannon CP, Lukas MA, Im K, Goodrich EL, et al. Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2017;6(10).
Berwanger O, Santucci EV, de Barros ESPGM, Jesuíno IA, Damiani LP, Barbosa LM, et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. Jama. 2018;319(13):1331-40.
Boccara F, Mary-Krause M, Potard V, Teiger E, Lang S, Hammoudi N, et al. HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. J Am Heart Assoc. 2020;9(17):e017578.
Bosiers MJ, Tran K, Lee JT, Donas KP, Veith FJ, Torsello G, et al. Incidence and prognostic factors related to major adverse cerebrovascular events in patients with complex aortic diseases treated by the chimney technique. Journal of vascular surgery. 2018;67(5):1372-9.
Chattopadhyay S, George A, John J, Sathyapalan T. Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes. Eur Heart J. 2018;39(29):2740-5.
Dieter BP, Daratha KB, McPherson SM, Short R, Alicic RZ, Tuttle KR. Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial. American journal of nephrology. 2019;49(5):359-67.
Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, et al. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017;6(10).
Gao R, Wu Y, Liu H, Su G, Yuan Z, Zhang A, et al. Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. Cardiovascular drugs and therapy. 2018;32(1):47-56.
Harris DE, Lacey A, Akbari A, Obaid DR, Smith DA, Jenkins GH, et al. Early Discontinuation of P2Y(12) Antagonists and Adverse Clinical Events Post-Percutaneous Coronary Intervention: A Hospital and Primary Care Linked Cohort. J Am Heart Assoc. 2019;8(21):e012812.
Hoshino M, Yonetsu T, Usui E, Kanaji Y, Ohya H, Sumino Y, et al. Clinical Significance of the Presence or Absence of Lipid-Rich Plaque Underneath Intact Fibrous Cap Plaque in Acute Coronary Syndrome. J Am Heart Assoc. 2019;8(9):e011820.
Jakimov T, Mrdovi? I, Filipovi? B, Zdravkovi? M, Djokovi? A, Hini? S, et al. Comparison of RISK-PCI, GRACE, TIMI risk scores for prediction of major adverse cardiac events in patients with acute coronary syndrome. Croatian medical journal. 2017;58(6):406-15.
Karjalainen PP, Airaksinen JK, de Belder A, Romppanen H, Kervinen K, Sia J, et al. Long-term outcome of early percutaneous coronary intervention in diabetic patients with acute coronary syndrome: insights from the BASE ACS trial. Annals of medicine. 2016;48(5):376-83.
Wang W, Wang CS, Ren D, Li T, Yao HC, Ma SJ. Low serum prealbumin levels on admission can independently predict in-hospital adverse cardiac events in patients with acute coronary syndrome. Medicine. 2018;97(30):e11740.
Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circulation Cardiovascular interventions. 2017;10(9).
Puurunen VP, Kiviniemi A, Lepojärvi S, Piira OP, Hedberg P, Junttila J, et al. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease. Annals of medicine. 2017;49(5):448-54.
Liu J, Quan J, Li Y, Wu Y, Yang L. Blood homocysteine levels could predict major adverse cardiac events in patients with acute coronary syndrome: A STROBE-compliant observational study. Medicine. 2018;97(40):e12626.
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020;41(42):4114-23.
Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP, et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA cardiology. 2019;4(4):314-20.
Jia S-D, Yao Y, Song Y, Tang X-F, Zhao X-Y, Gao R-L, et al. Two-Year Outcomes after Left Main Coronary Artery Percutaneous Coronary Intervention in Patients Presenting with Acute Coronary Syndrome. Journal of Interventional Cardiology. 2020:1-8.
Park S, Lee S, Kim Y, Lee Y, Kang MW, Han K, et al. Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons. Annals of Internal Medicine. 2019;171(12):875-84.
Yang J-H, Shih H-M, Pan Y-C, Chang S-S, Li C-Y, Yu S-H. Early Dual-Antiplatelet Therapy at the Emergency Department Is Associated with Lower In-Hospital Major Adverse Cardiac Event Risk among Patients with Non-ST-Elevation Myocardial Infarction. Cardiology Research & Practice. 2021:1-7.
Bansilal S, Castellano JM, Garrido E, Wei HG, Freeman A, Spettell C, et al. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. Journal of the American College of Cardiology (JACC). 2016;68(8):789-801.
Tan X, Youqin Z, Nan L, Zhuoqiao H, Xi S, Xuerui T, et al. Double product reflects the association of heart rate with MACEs in acute coronary syndrome patients treated with percutaneous coronary intervention. BMC Cardiovascular Disorders. 2017;17:1-7.
Tayeh O, Rizk A, Mowafy A, Salah S, Gabr K. Cystatin-C as a predictor for major adverse cardiac events in patients with acute coronary syndrome. The Egyptian Heart Journal. 2012;64(3):87-95.
Edmondson D, Rieckmann N, Shaffer JA, Schwartz JE, Burg MM, Davidson KW, et al. Posttraumatic stress due to an acute coronary syndrome increases risk of 42-month major adverse cardiac events and all-cause mortality. Journal of Psychiatric Research. 2011;45(12):1621-6.
Sari DP, Mudjaddid E, Ginanjar E, Muhadi. Relationship between Symptoms of Depression and Anxiety with Major Adverse Cardiac Event in 7 days in Patients with Acute Coronary Syndrome in Cipto Mangunkusumo Hospital. Jurnal Penyakit Dalam Indonesia. 2018;5.
Martalena D, Nasution SA, Purnamasari D, Harimurtin K. The Effect of Hyperglycemia on Admission on Survival of Major Adverse Cardiac Events during Hospitalization in Patients with Acute Coronary Syndrome in Coronary Care Unit Cipto Mangunkusumo Hospital, Jakarta. EJKI. 2013;1.
Park KH, Jeong MH, Hong YJ, Ahn Y, Kim HK, Koh YY, et al. Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study). Yonsei medical journal. 2018;59(1):72-9.
Downloads
Published
Versions
- 2022-08-20 (2)
- 2022-08-20 (1)
